The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2024 | Managing patients with myeloma who are penta-refractory and have exhausted BCMA-targeting therapies
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the limited treatment options for patients with multiple myeloma (MM) who are penta-refractory and have failed prior anti-BCMA therapy, noting the promise of targeting GPRC5D as a new therapeutic approach. She highlights alternative agents, such as melflufen and selinexor, but acknowledges that clinical outcomes in this patient population remain suboptimal. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
